Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), discusses with Proactive's Andrew Scott their licensing deal with FTSE 250-listed Indivior for its addiction behaviour suppressant, C4X3256.
It is the first major partnership for C4X, which will receive US$10mln up front and a further US$284mln dependent on how successful the drug proves.
Meet ANGLE plc, Faron Pharmaceuticals Ltd, Alliance Pharma plc, Clinigen Group PLC and Avacta Group Plc at our event,London, 05 April 2018.Register here >>